to page content
to site navigation
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
There are a great number of healthcare apps available to different players in healthcare. When it comes to the patient market for healthcare apps, a quality experience and a way for patients to be involved are the key.
Innovation is often called "disruptive" in the healthcare industry, and the first step toward making that innovation successful is to get a product's targeted users to accept change. Founder of Fitzeal, Clifton Dawson, found a way to get people to use his product by focusing on a strong user support system.
Kim Popovits, CEO of Genomic Health Inc., gave the keynote speech at a Life Science Ventures Summit hosted by the Kauffman Foundation. Popovits closed her speech by stressing the importance of having a company that is “healthy” (34:56-40:22).
See who made this week's list
How will medtech and biotech companies be affected by the recently approved Leahy-Smith America Invents Act? Read more for five things these companies need to know about the modernized patent laws.
The United States is joining the rest of the world in its approach to patent filings. But what does that mean in the completely global world of medical and pharmaceutical treatments, therapies and technologies depending on a strong and reliable patent system? Read how new American patent law will change medical business plans.
Physician-consultants and medical device startups often don’t realize that failure to draft a tight physician-consultant contract could result in violations of federal laws and criminal and civil penalties. Read more about the guidelines for these contracts.
Investors in bioscience are looking not just for financial returns, but societal returns over the long haul in a global economy. And that will take collaborative efforts and a crowdsourcing of expertise as well as capital.
Healthcare entrepreneurs who have hit the intellectual property speed bump can relate to the appropriately named session, "Reducing Drag: New Approaches to IP Negotiation and Technology Licensing," at the Partnering for Cures conference earlier this week in New York City.
Is venture capital still viable as a model for funding new bioscience research, products and businesses?
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.